Last updated on June 2018

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy


Brief description of study

This is a multi-site, placebo-controlled, double-blind, randomized-withdrawal study evaluating the durability of clinical benefit of a study drug for patients with symptomatic neurogenic orthostatic hypotension. This study has a duration of up to 36 weeks, consisting of 5 periods: 

  1. Screening Period: up to 4 weeks duration; 
  2. Open-Label Titration Period (Titration Period): up to 4 weeks duration; 
  3. Open-Label Treatment Period (Open-Label Period): 12 weeks duration; 
  4. Double-Blind Treatment Period (Double-Blind Period): 12 weeks duration; 
  5. Safety Follow-Up Period: 4 weeks duration.

Clinical Study Identifier: TX207239

Contact Investigators or Research Sites near you

Start Over

EvergreenHealth Research Program

EvergreenHealth Research Program
Kirkland, WA USA
  Connect »